Stocksigma LogoStocksigma Logo

Mukka Proteins Confirms Zero Deviation in Preferential Issue Fund Utilization

Mukka Proteins Limited reported nil deviation in the utilization of funds raised via its preferential issue of warrants for the quarter ended 30th Sep'26

Mukka Proteins Confirms Zero Deviation in Preferential Issue Fund Utilization

Mukka Proteins Ltd 路 Others (Uncategorized) 路 07 Nov 2026, 6:06 pm

Mukka Proteins Confirms Zero Deviation in Preferential Issue Fund Utilization Mukka Proteins Limited reported nil deviation in the utilization of funds raised via its preferential issue of warrants for the quarter ended 30th Sep'26. The company allotted warrants on 9th Sep'26, raising Rs 47.00 cr. Of the total allocation, Rs 11.75 cr has been utilized toward working capital requirements against an earmarked Rs 35.00 cr. No funds have been deployed yet from the allocations for business expansion (Rs 5.00 cr) or general corporate purposes (Rs 7.00 cr). The Audit Committee reviewed and approved the statement on 7th Nov'26.

Original exchange filing (PDF)

More announcements from Mukka Proteins Ltd

All Mukka Proteins Ltd announcements